Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging

Détails

ID Serval
serval:BIB_412DF566D90D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging
Périodique
Clin Breast Cancer
Auteur(s)
Chereau E., Uzan C., Balleyguier C., Chevalier J., de Paillerets B. B., Caron O., Rimareix F., Mathieu M. C., Koskas M., Bourgier C., Andre F., Dromain C., Delaloge S.
ISSN-L
1938-0666 (Electronic)1526-8209 (Linking)
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
10
Numéro
2
Pages
113-8
Langue
anglais
Notes
Chereau, ElisabethUzan, CatherineBalleyguier, CorinneChevalier, Juliede Paillerets, Brigitte BressacCaron, OlivierRimareix, FrancoiseMathieu, Marie-ChristineKoskas, MartinBourgier, CelineAndre, FabriceDromain, ClarisseDelaloge, Suzetteeng2010/03/20 06:00Clin Breast Cancer. 2010 Apr;10(2):113-8. doi: 10.3816/CBC.2010.n.022.
Résumé
BACKGROUND: Breast magnetic resonance imaging (MRI) with conventional screening methods improves sensitivity in high-risk patients without benefits on specific survival. We evaluated the characteristics, treatments, and prognostic features of breast cancers diagnosed among BRCA1/2 mutation carriers either inside or outside screening programs that included MRI. PATIENTS AND METHODS: Two groups of patients diagnosed with a new breast cancer between 2001 and 2007 were compared: group 1, patients included in an intensive screening program; and group 2, patients outside of this program. RESULTS: Twenty-one patients met inclusion criteria for group 1, and 102 for group 2. Seventy-four percent and 65%, respectively, were BRCA1 mutation carriers. Tumors in both groups had the same characteristics (pN, grade, estrogen receptor, progesterone receptor, HER2 expression), except for smaller tumor size in group 1 (median, 6 mm vs. 22 mm; P < .0001). Group 1 patients had more frequent sentinel node procedures (57% vs. 28%; P = .021) and less commonly received chemotherapy (43% vs. 86%; P < .0001). The 3-year disease-free survival (93% vs. 74%; P = .1) and the 3-year overall survival (100% vs. 92%; P = .2) did not differ between groups. CONCLUSION: MRI might provide improvement in BRCA1/2 carriers in terms of smaller tumor size and treatment morbidity. However, because of aggressive intrinsic characteristics, this does not turn into significant survival benefits.
Mots-clé
Adult, Aged, Antineoplastic Agents/therapeutic use, Breast Neoplasms/*diagnosis/mortality/*therapy, Female, Genes, BRCA1, Genes, BRCA2, Genetic Predisposition to Disease, Heterozygote, Humans, Kaplan-Meier Estimate, Magnetic Resonance Imaging, Mass Screening/methods, Middle Aged, Mutation, Prognosis, Radiotherapy, Sentinel Lymph Node Biopsy, Treatment Outcome, Young Adult
Création de la notice
16/09/2016 11:13
Dernière modification de la notice
03/03/2018 16:31
Données d'usage